Liquidia Technologies Inc
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The comp… Read more
Liquidia Technologies Inc (LQDA) - Total Liabilities
Latest total liabilities as of September 2025: $253.93 Million USD
Based on the latest financial reports, Liquidia Technologies Inc (LQDA) has total liabilities worth $253.93 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Liquidia Technologies Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how Liquidia Technologies Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Liquidia Technologies Inc Competitors by Total Liabilities
The table below lists competitors of Liquidia Technologies Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
L&F Co. Ltd
KQ:066970
|
Korea | ₩2.24 Trillion |
|
Western Securities Co Ltd
SHE:002673
|
China | CN¥80.68 Billion |
|
Carl Zeiss Meditec AG
PINK:CZMWF
|
USA | $1.28 Billion |
|
Zhongfu Straits Pingtan Development Co Ltd
SHE:000592
|
China | CN¥1.32 Billion |
|
Guangdong Fenghua Advanced Technology Holding Co Ltd
SHE:000636
|
China | CN¥4.22 Billion |
|
Nuvei Corp
NASDAQ:NVEI
|
USA | $3.13 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down Liquidia Technologies Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.20 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 11.52 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.92 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Liquidia Technologies Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Liquidia Technologies Inc (2016–2024)
The table below shows the annual total liabilities of Liquidia Technologies Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $153.04 Million | +115.43% |
| 2023-12-31 | $71.04 Million | +83.20% |
| 2022-12-31 | $38.78 Million | +36.23% |
| 2021-12-31 | $28.46 Million | +0.06% |
| 2020-12-31 | $28.45 Million | -16.08% |
| 2019-12-31 | $33.89 Million | +10.30% |
| 2018-12-31 | $30.73 Million | -36.68% |
| 2017-12-31 | $48.54 Million | +81.57% |
| 2016-12-31 | $26.73 Million | -- |